CVE:ACST Acasti Pharma (ACST) Stock Price, News & Analysis C$0.58 +0.01 (+1.75%) As of 03/27/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acasti Pharma Stock (CVE:ACST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acasti Pharma alerts:Sign Up Key Stats Today's RangeC$0.56▼C$0.5850-Day RangeC$0.58▼C$0.5852-Week RangeC$0.47▼C$1.66Volume2,450 shsAverage Volume6,576 shsMarket CapitalizationC$18.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada. Read More Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACST Stock News HeadlinesOTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCROctober 29, 2024 | msn.comLife Sciences Virtual Investor Forum Agenda Announced for September 19thSeptember 16, 2024 | finance.yahoo.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 7 at 2:00 AM | Banyan Hill Publishing (Ad)ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025August 9, 2024 | markets.businessinsider.comAcasti Pharma Inc. (ACST)April 6, 2024 | finance.yahoo.comAcasti Pharma Inc. Class AMarch 14, 2024 | edition.cnn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12February 25, 2024 | msn.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsFebruary 12, 2024 | finance.yahoo.comSee More Headlines ACST Stock Analysis - Frequently Asked Questions How have ACST shares performed this year? Acasti Pharma's stock was trading at C$0.58 at the beginning of the year. Since then, ACST shares have increased by 0.0% and is now trading at C$0.58. How do I buy shares of Acasti Pharma? Shares of ACST stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include Genius Brands International (GNUS), Tesla (TSLA), Workhorse Group (WKHS), SCYNEXIS (SCYX) and Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolCVE:ACST Previous SymbolCVE:APO CIKN/A Webwww.acastipharma.com Phone+1-450-6864555FaxN/AEmployees32Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$10.54 million Net Margins-388.46% Pretax MarginN/A Return on Equity-35.76% Return on Assets-8.25% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio9.41 Sales & Book Value Annual SalesC$2.71 million Price / Sales6.71 Cash FlowC$0.93 per share Price / Cash Flow0.63 Book ValueC$0.86 per share Price / Book0.67Miscellaneous Outstanding Shares31,369,490Free FloatN/AMarket CapC$18.19 million OptionableNot Optionable Beta1.22 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (CVE:ACST) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
